Morgan Stanley assumed coverage of Absci (ABSI) with an Overweight rating and $7 price target Absci has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The upcoming value inflection points with the second half of 2025 interim data readout for TL1A asset ABS-101 and second half of 2026 Phase I interim proof of concept efficacy readout for PRLR ABS-201 present potential results skewed to the upside for Absci, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABSI:
- Largest borrow rate increases among liquid names
- Absci Elects New Board Members at Annual Meeting
- Absci Corp’s Earnings Call: A Promising Outlook
- Buy Rating for Absci: Strategic Advancements and Promising Clinical Trials Highlight Growth Potential
- Promising Developments and Strategic Initiatives Drive Buy Rating for Absci